Bristow M, Port J D
University of Colorado Health Sciences Center, Division of Cardiology, Denver 80262, USA.
Scand Cardiovasc J Suppl. 1998;47:45-55. doi: 10.1080/140174398428045.
In summary, beta-blockade is currently the most promising "new" treatment undergoing Phase III testing in chronic heart failure. Multiple studies on the effects of these agents on LV function and chamber characteristics as well as limited survival data strongly suggest that these agents produce a beneficial effect on the natural history of heart failure. If this promise is borne out in the currently active or planned large-scale clinical trials, this form of therapy will emerge as the most valuable treatment available for chronic heart failure.
